Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

Sanofi Looks Cheap, but Dupixent Cliff and Insmed Talk Cloud the Picture

Published Nov 20, 2026
Share:
Summary:
  • Sanofi trades at roughly 9 times next‑12‑months earnings, the lowest multiple among the 10 biggest pharma companies by sales, versus a 17.3 group average.
  • Dupixent is the growth engine today, but it will start to face loss of patent protection in 2031, and skeptics doubt the current pipeline can fully backfill those sales.
  • Sanofi is weighing a bid for Insmed, valued around $31.6 billion, and its shares fell 2.9% on the report before trimming the drop the next day.

Valuation: the stock looks cheap on paper

After a rally since early October, Sanofi still changes hands at about 9 times projected earnings for the next year. That makes it the least expensive name among the world's 10 largest drugmakers by sales, compared with a peer average multiple near 17.3 based on analyst estimates.

Despite that low bar, the stock has lagged bigger rivals this year. Total return is 8.9% including dividends, trailing the Stoxx Europe 600 Health Care Index's 11%.

Dupixent is the engine - and the clock is ticking

Sales are booming for Dupixent, Sanofi's eczema and asthma therapy. But the medicine is expected to begin losing exclusivity in 2031, and many investors doubt Sanofi's experimental pipeline can fully replace that cash flow.

Some analysts think the market is leaning too hard into that worry. Intron Health's Naresh Chouhan this month upgraded his view from hold to buy; Bloomberg's tracking shows he set the most optimistic target price on the stock, implying a potential 41% rise from current levels. He expects Dupixent sales to climb from €15.7 billion last year to €34 billion in 2031. BNP Paribas's Peter Verdult also upgraded to outperform, arguing that worries about a thin pipeline are already baked into the valuation while near-term Dupixent earnings are being underestimated.

M&A talk, balance sheet room and the Insmed angle

One way to prepare for life after Dupixent is to buy growth. Sanofi is evaluating a takeover of US biotech Insmed, according to people familiar with the situation. Insmed, which is worth about $31.6 billion, sells two approved medicines for respiratory conditions. Both companies have declined to discuss any possible transaction.

When company outlooks shift, it's helpful to stay informed, so sign up for the free Market Briefs newsletter for concise daily context.

It would be the largest pharma deal since Pfizer's late-2023 purchase of Seagen Inc. for $43 billion. The news knocked Sanofi shares by 2.9% on Thursday, though they recouped part of that move Friday.

Jefferies analyst Michael Leuchten estimates Sanofi could deploy more than €25 billion, or $27.5 billion, without harming its dividend or credit rating, making a bid for Insmed plausible. In his words, "a sizeable M&A transaction should provide greater stability through the Dupixent patent cliff and, hence, create time for Sanofi to reload its pipeline." His takeaway: it looks big, but it is "doable, digestible and directionally" in line with management's aims.

Leadership, strategy and what it means for your portfolio

Chief Executive Officer Belén Garijo, who took the helm this year after a stint at Merck KGaA, is signaling the near- and long-term focus. "The whole organization is focused on managing Sanofi's post-Dupixent trajectory over the next decade," she said last month, adding, "Our priority is to protect earnings through Dupixent's loss of exclusivity."

Analysts are weighing her appetite for bold deals. Alphavalue's Abhishek Raval put it this way: "Bold moves rarely come without risks, and it might be the right time for Sanofi's management to take some calculated chances," noting that buying Insmed "would certainly be a massive step in answering the market's pressing question around Sanofi's life after Dupixent."

The bottom line: a bargain multiple, a cash-rich flagship drug, and a looming patent deadline. Add in upgrade momentum and real M&A capacity, and you get a stock where execution on pipeline and deals will likely drive whether that discount narrows into 2027 and beyond.

In uncertain industries, a clear daily briefing saves time, join Market Briefs to get five-minute explainers on markets, economy, crypto and real estate.

Disclosure

Recent News

1 2 3 … 133

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 20, 2026
Anthropic Stock at $1.5 Trillion: Why This IPO Isn't Amazon in 1997

Anthropic has gone public at a valuation of about $1.5 trillion, while Amazon went public in 1997 at around $440 million. Anthropic has about $33 billion in revenue this year and no profit, and investors are paying more than 40 times its sales, against about 3 times for Amazon. Briefs Finance CEO Jaspreet Singh says nobody knows what comes next, and that long-term investors use downturns to buy instead of panic selling.

Read More
November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
1 2 3 … 33
Share via
Copy link